Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice

N Sauer; F Reining; C Schulze Zur Wiesch; T Burkhardt; J Aberle

doi:10.1055/s-0034-1387793

Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice

Standard

Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice. / Sauer, N; Reining, F; Schulze Zur Wiesch, C; Burkhardt, T; Aberle, J.

in: HORM METAB RES, 17.09.2014.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sauer, N, Reining, F, Schulze Zur Wiesch, C, Burkhardt, T & Aberle, J 2014, 'Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice', HORM METAB RES. https://doi.org/10.1055/s-0034-1387793

APA

Sauer, N., Reining, F., Schulze Zur Wiesch, C., Burkhardt, T., & Aberle, J. (2014). Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice. HORM METAB RES. https://doi.org/10.1055/s-0034-1387793

Vancouver

Sauer N, Reining F, Schulze Zur Wiesch C, Burkhardt T, Aberle J. Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice. HORM METAB RES. 2014 Sep 17. https://doi.org/10.1055/s-0034-1387793

Bibtex

@article{a090b4a78ba947c9a3a0dd9aa069f8b9,

title = "Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice",

abstract = "The aim of the work was to investigate whether continuation of treatment, side effects, and effect on weight loss of GLP-1 agonists in obese patients without diabetes are equally promising in daily clinical-practice-settings compared to controlled clinical trials. Obese patients without diabetes of our interdisciplinary obesity centre were treated off-label with GLP-1-agonists for different time periods. Application was started with low-dose and increased if side effects were tolerable. Monthly costs were € 125 for daily applications of 1.2 mg liraglutide or 10 μg exenatide twice daily. Data were obtained by telephone interviews about baseline characteristics, weight loss, sensation of satiation, duration of therapy, side effects, and reasons for discontinuation. Of 43 included cases (5 males, mean age 43±11 years, mean weight 107±24 kg, mean excess weight 35±21 kg) 7 were treated with exenatide and 36 with liraglutide. Excess weight loss in linear regression models was 6.7% per month (p <0.05) under control of age, sex, initial weight, and type of GLP-1 analogue treatment and did not significantly differ between liraglutide and exenatide. Overall, 58% of patients reported side effects mostly concerning the gastrointestinal tract. Surprisingly no patient reported vomiting. One patient developed a severe pancreatitis. At time of telephone interview only 30.2% were continuing treatment. Mean treatment duration was 2.98±2.71 months. Common reasons for discontinuation of treatment were no/little effect on weight loss (27.9%), intolerable side effects (20.9%), or financial reasons (14%). GLP-1 agonist treatment in obese patients without diabetes also correlates with significant weight loss in clinical practice. However, side effects and discontinuation of treatment are common. Therefore, long-term effect on weight loss might not be as promising as suggested by data from clinical trials.",

author = "N Sauer and F Reining and {Schulze Zur Wiesch}, C and T Burkhardt and J Aberle",

note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",

year = "2014",

month = sep,

day = "17",

doi = "10.1055/s-0034-1387793",

language = "English",

journal = "HORM METAB RES",

issn = "0018-5043",

publisher = "Georg Thieme Verlag KG",

}

RIS

TY - JOUR

T1 - Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice

AU - Sauer, N

AU - Reining, F

AU - Schulze Zur Wiesch, C

AU - Burkhardt, T

AU - Aberle, J

PY - 2014/9/17

Y1 - 2014/9/17

N2 - The aim of the work was to investigate whether continuation of treatment, side effects, and effect on weight loss of GLP-1 agonists in obese patients without diabetes are equally promising in daily clinical-practice-settings compared to controlled clinical trials. Obese patients without diabetes of our interdisciplinary obesity centre were treated off-label with GLP-1-agonists for different time periods. Application was started with low-dose and increased if side effects were tolerable. Monthly costs were € 125 for daily applications of 1.2 mg liraglutide or 10 μg exenatide twice daily. Data were obtained by telephone interviews about baseline characteristics, weight loss, sensation of satiation, duration of therapy, side effects, and reasons for discontinuation. Of 43 included cases (5 males, mean age 43±11 years, mean weight 107±24 kg, mean excess weight 35±21 kg) 7 were treated with exenatide and 36 with liraglutide. Excess weight loss in linear regression models was 6.7% per month (p <0.05) under control of age, sex, initial weight, and type of GLP-1 analogue treatment and did not significantly differ between liraglutide and exenatide. Overall, 58% of patients reported side effects mostly concerning the gastrointestinal tract. Surprisingly no patient reported vomiting. One patient developed a severe pancreatitis. At time of telephone interview only 30.2% were continuing treatment. Mean treatment duration was 2.98±2.71 months. Common reasons for discontinuation of treatment were no/little effect on weight loss (27.9%), intolerable side effects (20.9%), or financial reasons (14%). GLP-1 agonist treatment in obese patients without diabetes also correlates with significant weight loss in clinical practice. However, side effects and discontinuation of treatment are common. Therefore, long-term effect on weight loss might not be as promising as suggested by data from clinical trials.

AB - The aim of the work was to investigate whether continuation of treatment, side effects, and effect on weight loss of GLP-1 agonists in obese patients without diabetes are equally promising in daily clinical-practice-settings compared to controlled clinical trials. Obese patients without diabetes of our interdisciplinary obesity centre were treated off-label with GLP-1-agonists for different time periods. Application was started with low-dose and increased if side effects were tolerable. Monthly costs were € 125 for daily applications of 1.2 mg liraglutide or 10 μg exenatide twice daily. Data were obtained by telephone interviews about baseline characteristics, weight loss, sensation of satiation, duration of therapy, side effects, and reasons for discontinuation. Of 43 included cases (5 males, mean age 43±11 years, mean weight 107±24 kg, mean excess weight 35±21 kg) 7 were treated with exenatide and 36 with liraglutide. Excess weight loss in linear regression models was 6.7% per month (p <0.05) under control of age, sex, initial weight, and type of GLP-1 analogue treatment and did not significantly differ between liraglutide and exenatide. Overall, 58% of patients reported side effects mostly concerning the gastrointestinal tract. Surprisingly no patient reported vomiting. One patient developed a severe pancreatitis. At time of telephone interview only 30.2% were continuing treatment. Mean treatment duration was 2.98±2.71 months. Common reasons for discontinuation of treatment were no/little effect on weight loss (27.9%), intolerable side effects (20.9%), or financial reasons (14%). GLP-1 agonist treatment in obese patients without diabetes also correlates with significant weight loss in clinical practice. However, side effects and discontinuation of treatment are common. Therefore, long-term effect on weight loss might not be as promising as suggested by data from clinical trials.

U2 - 10.1055/s-0034-1387793

DO - 10.1055/s-0034-1387793

M3 - SCORING: Journal article

C2 - 25230325

JO - HORM METAB RES

JF - HORM METAB RES

SN - 0018-5043

ER -